Status:
UNKNOWN
Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II
Lead Sponsor:
The University of Hong Kong
Conditions:
Exercise Physiology
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
The major aims are to determine the effect of acute (single dose) blockade of ANGII receptor 1 (AT1) on the EPO response to a single session of endurance exercise, as well as determine the effect of c...
Detailed Description
Physical activity, particularly when comprised of endurance training (ET) leading to cardiovascular adaptations, is considered the most effective intervention to augment life expectancy. Major health ...
Eligibility Criteria
Inclusion
- Healthy status, absence of current medical symptoms or medication limiting incremental exercise testing
- No history of cardiac, pulmonary or kidney disease.
Exclusion
- \- Individuals fulfilling the above criteria but currently involved in regular exercise training (\> 5 hr/week)
Key Trial Info
Start Date :
March 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05269615
Start Date
March 20 2023
End Date
September 30 2024
Last Update
May 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
School of Public Health
Hong Kong, Hong Kong